# QLS5132 Combination Therapy in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07453394/  
OnCo record `nct07453394` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of bevacizumab, olaparib, iparomlimab and tuvonralimab, QL2107 and other drugs in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

QLS5132 Combination Therapy in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07453394 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 626 participants, started 2026-04 and due to reach its primary completion in 2027-04. Interventions recorded: QLS5132; Bevacizumab; QLS5132; Platinum; Bevacizumab; QLS5132; Olaparib; Bevacizumab; QLS5132; QL1706; QL2107; QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin. Conditions listed: Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC); Endometrial Cancer; Advanced Solid Tumors; Ovarian Cancer. Primary outcome: Incidence and severity of adverse events; Maximum tolerated dose (MTD); Recommended Phase 2 Dose (RP2D). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07453394
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenous QLS5132 Combination Therapy in Participants With Advanced Solid Tumors
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 626

## Sources

- ClinicalTrials.gov NCT07453394: https://clinicaltrials.gov/study/NCT07453394

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/), [Olaparib](https://onco.cc/drugs/olaparib/), [QL2107](https://onco.cc/drugs/ql2107/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07453394.json